Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-5288 in Adult Patients With Alzheimer's Disease
NCT07214727Phase 1Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Mar 2030
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing ALN-5288 with Placebo + ALN-5288 (2 arms). Primary endpoints: Frequency of Adverse Events up to 32 months and Severity of Adverse Events up to 32 months. Started Oct 2025; status: recruiting.
02
Drugs
ALN-5288
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07214727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214727.